---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-028015"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T04:55:10.547208+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Leap reports positive sirexatamab CRC data: 32% higher ORR, 3.5mo PFS in high DKK1 patients

## Summary
- High DKK1 patients: sirexatamab arm ORR 48% vs 15.8% control; median PFS 9.36 vs 5.88 mo (HR 0.46); OS HR 0.09.
- No prior anti-VEGF patients: ORR 55.1% vs 32.6%; median PFS 10.94 vs 8.34 mo (HR 0.59); OS immature.
- FY2024 net loss $67.6M ($81.4M in 2023); R&D expenses $57.2M ($73.2M in 2023).
- Cash and equivalents $47.2M at Dec 31, 2024; engaged financial advisor for business development.
- FL-501 abstract accepted at AACR 2025; preclinical data to be presented April 25-30.

## SEC filing metadata
- accession: 0001104659-25-028015
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465925028015/0001104659-25-028015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465925028015/tm2510101d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-028015
- JSON: https://secwatch.observer/filing/0001104659-25-028015.json
- Plain text: https://secwatch.observer/filing/0001104659-25-028015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.